Search results
Showing 401 to 414 of 414 results for cost benefit of cancer drugs
Quality standards: process guide
Improved agreement means NICE now recommends lung cancer treatment
Thousands of people with non-small-cell lung cancer (NSCLC) will benefit from draft guidance published today by NICE.
New agreement means NICE recommends combination treatment for some lymphoma patients
Hundreds of people with a form of blood cancer will benefit from a new treatment following the publication of draft guidance by NICE.
New drugs 'a major benefit' for patients with chronic hepatitis C
NICE has recommended the use of boceprevir (Victrelis) and telaprevir (Incivo), both in combination with peginterferon alfa and ribavirin, as options for the treatment of the most common strain of hepatitis C in adults, in latest guidance.
NICE recommends 'game changing' histology independent cancer drug
Larotrectinib (also called Vitrakvi and made by Bayer), is a new treatment for a range of cancers, has been recommended for use in the Cancer Drugs Fund (CDF).
Uptake of NICE-approved medicines on the NHS to treat cardiovascular disease, diabetes and osteoporosis is higher than expected, latest figures reveal.
Around 5,700 cases of multiple myeloma are diagnosed each year in the UK
Hundreds of people with cervical cancer are set to receive the first immunotherapy drug for an advanced form of the disease as NICE publishes final draft guidance today (Wednesday 29 March 2023) recommending its use in the Cancer Drugs Fund (CDF).
More than 1,000 people each year will benefit from NICE's recommendation
NICE recommends new drug osimertinib for hundreds of people with lung cancer
Hundreds of people with lung cancer will now have access to new drug osimertinib, also known as Tagrisso, after NICE says it should be made available on the Cancer Drugs Fund (CDF).
The NHS should offer weight loss surgery to thousands more people in order to tackle an epidemic of type 2 diabetes, says NICE.
Ovarian cancer patients to have NICE-approved drug combination option on Cancer Drugs Fund
A potentially life-extending drug combination for some people with advanced, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer will now be available on the Cancer Drugs Fund (CDF), following its approval by NICE in draft guidance published today.
An innovative life-extending drug for treating mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults is being recommended by NICE as an option for use within the Cancer Drugs Fund.
Triple therapy recommended by NICE for patients with multiple myeloma
The therapy has been recommended after a confidential discount was agreed between NHS England and the drug manufacturer Amgen.